Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 10, 2024 (filed on Apr 10, 2024)Insider Name:Fouse Jacqualyn AOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-7,791Price:$27.55
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Fouse Jacqualyn AOwnership Type:Direct OwnershipSecurities:Restricted stock unitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,934Price:--
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Fouse Jacqualyn AOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,934Price:--
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Foster-Cheek Kaye IOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,285Price:$31.62
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Foster-Cheek Kaye IOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,415Price:$31.99
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Foster-Cheek Kaye IOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-300Price:$32.21
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Washburn Theodore James Jr.Ownership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,913Price:$31.75
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Gheuens SarahOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,349Price:$32.57
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Gheuens SarahOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,293Price:$32.57
-
Mar 05, 2024 (filed on Mar 05, 2024)Insider Name:Jones CeciliaOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-672Price:$32.57
Filings by filing date
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Fouse Jacqualyn AOwnership Type:Direct OwnershipSecurities:Restricted stock unitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,934Price:--
-
Apr 10, 2024 (filed on Apr 10, 2024)Insider Name:Fouse Jacqualyn AOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-7,791Price:$27.55
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Fouse Jacqualyn AOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,934Price:--
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Foster-Cheek Kaye IOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,285Price:$31.62
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Foster-Cheek Kaye IOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,415Price:$31.99
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Foster-Cheek Kaye IOwnership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-300Price:$32.21
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Washburn Theodore James Jr.Ownership Type:Direct OwnershipSecurities:Common stockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,913Price:$31.75
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Gheuens SarahOwnership Type:Direct OwnershipSecurities:Restricted stock unitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,000Price:--
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Gheuens SarahOwnership Type:Direct OwnershipSecurities:Restricted stock unitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,834Price:--
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Gheuens SarahOwnership Type:Direct OwnershipSecurities:Stock options (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 88 Sidney Street CAMBRIDGE MA 02139 |
Tel: | N/A |
Website: | https://www.agios.com |
IR: | See website |
Key People | ||
Jacqualyn A. Fouse Chairman of the Board | Brian M. Goff Chief Executive Officer, Director | Cecilia Jones Chief Financial Officer |
James Burns Chief Legal Officer | Sarah Gheuens Head - Research and Development, Chief Medical Officer | Tsveta Milanova Chief Commercial Officer |
Business Overview |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD. |
Financial Overview |
For the fiscal year ended 31 December 2023, Agios Pharmaceuticals Inc revenues increased 88% to $26.8M. Net loss increased 52% to $352.1M. Revenues reflect Product revenue, net increase from $11.7M to $26.8M. Higher net loss reflects Gain on sale of contingent payments decrease from $127.9M (income) to $0K, Research and development increase of 8% to $278.5M (expense), Royalty income from gain on sale of onco decrease from $9.9M (income) to $0K. |
Employees: | 383 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,003M as of Dec 31, 2023 |
Annual revenue (TTM): | $26.82M as of Dec 31, 2023 |
EBITDA (TTM): | -$384.86M as of Dec 31, 2023 |
Net annual income (TTM): | -$352.09M as of Dec 31, 2023 |
Free cash flow (TTM): | -$297.06M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 56,194,847 as of Feb 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |